Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Receiving Gefitinib
Katsuyuki Hotta, Katsuyuki Kiura, Masahiro Tabata et al. · The Cancer Journal · 2005
UNLABELLED: Risk factors for the development of interstitial lung disease in patients with non-small cell lung cancer receiving gefitinib and the prognostic factors after interstitial lung disease development have not been established. The aim of this study was to retrospectively identify and evaluate these possible factors. PATIENTS AND METHODS: We reviewed the clinical records and radiographs of 365 consecutive patients with non-small cell lung cancer who received gefitinib in West Japan between 2000 and 2003. RESULTS: In total, 330 patients were eligible for interstitial lung disease evaluation, and 15 patients (4.5%) were finally confirmed to have developed interstitial lung disease by blinded expert review. Multivariate analysis revealed that preexisting pulmonary fibrosis, poor performance status, and prior thoracic irradiation were independent risk factors for interstitial lung disease, with odds ratios of 21.0 (95% confidence interval, 5.12-86.3, P < 0.0001), 9.70 (2.27-41.4, P = 0.001), and 4.33 (1.27-14.8, P = 0.019), respectively. Among the 15 patients who developed interstitial lung disease, eight have died of the condition. Short interval from the initiation of gefitinib treatment to the onset of interstitial lung disease, acute interstitial pneumonia pattern, and the presence of pre-existing pulmonary fibrosis were associated with poor prognosis. DISCUSSION: Our results suggest the importance of patient selection for gefitinib treatment based on interstitial lung disease risk factors in the Japanese population identified.
Cited by 74 works. doi:10.1097/00130404-200509000-00010
Authors
- Katsuyuki Hotta
- Katsuyuki Kiura
- Masahiro Tabata
- Shingo Harita
- Kenichi Gemba
- Toshiro Yonei
- Akihiro Bessho
- Tadashi Maeda
- Tomonori Moritaka
- Takuo Shibayama
- Keisuke Matsuo
- Katsuya Kato
- Arihiko Kanehiro
- Yasushi Tanimoto
- Keitaro Matsuo
- Hiroshi Ueoka
- Mitsune Tanimoto
References
- Reporting results of cancer treatment
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
- Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.
- Severe acute interstitial pneumonia and gefitinib
- Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
- Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib
- Radiation-induced and chemotherapy-induced pulmonary injury
- Overview of the Tolerability of Gefitinib (IRESSA???) Monotherapy